Table 3.
Characteristics of patients with and without HBV Recurrence
| HBV Recurrence | No HBV Recurrence | P value | |
|---|---|---|---|
| No. of patients | 13 (6.9) | 174 (93.0) | |
| Gender, male | 13 (100) | 128 (73.6) | 0.031 |
| Age, years | 53.5 ± 9.4 | 52.3 ± 10.3 | 0.708 |
| Race | 0.034 | ||
| Caucasian | 10 (76.9) | 68 (39.2) | |
| Asian | 2 (15.4) | 78 (44.8) | |
| African American | 1 (7.7) | 18 (10.3) | |
| Other | 0 | 10 (5.7) | |
| OLT Indication at transplant | 0.686 | ||
| End-stage Cirrhosis | 5 (38.5) | 68 (39.1) | |
| HCC | 8 (61.5) | 89 (51.1) | |
| Acute Liver Failure | 0 | 17 (9.8) | |
| Labs at listing | |||
| HBeAg (+) | 7/11 (63.6) | 44/154 (28.6) | 0.010 |
| HBV DNA detectable | 8/12 (66.7) | 73/156 (46.8) | 0.177 |
| HBV DNA >5 log10 copies/mL | 7/12 (58.3) | 44/156 (28.2) | 0.027 |
| HBV-DNA log10 copies/mL | 5.3 ± 2.98 | 3.50 ± 2.1 | 0.001 |
| Labs at transplant | |||
| HBeAg (+) | 4/9 (44.4) | 40/145 (27.6) | 0.220 |
| HBV DNA detectable | 9/10 (90) | 97/155 (62.6) | 0.103 |
| HBV DNA >5 log10 copies/mL | 8/10 (80) | 54/155 (34.8) | 0.003 |
| HBV DNA >3 log10 copies/mL | 9/10 (90) | 77/155 (49.7) | 0.017 |
| HBV-DNA log10 copies/mL | 7.0 ± 2.45 | 3.9 ± 2.0 | <0.001 |
| HBIG regimen | 13/13 | 170/174 | 0.733 |
| IV high dose | 4 (30.7) | 43 (25.3) | |
| IV low dose | 1 (7.7) | 39 (22.9) | |
| IM low dose | 5 (38.5) | 68 (40.0) | |
| Finite duration | 3 (23.0) | 20 (11.8) | |
| Antiviral treatment pre-OLT | 11 (84.6) | 127 (73.0) | 0.285 |
| Total duration of treatment before OLT, months | 11.8 ± 9.2 | 21.4 ± 22.0 | 0.153 |
| Treatment at the time of transplant | 0.280 | ||
| LAM | 10/11 (90.9) | 84/127 (66.1) | |
| LAM+ADV/TDF | 1/11 (9.1) | 17/127 (13.5) | |
| Non-LAM | 0 | 26/127 (20.4) | |
| Virologic breakthrough prior to OLT | 3/11 (27.2) | 22/127 (17.3) | 0.209 |
| Post-OLT prophylaxis | 0.898 | ||
| HBIG only | 0 | 2 (1.1) | |
| Antiviral only | 0 | 4 (2.2) | |
| HBIG+antiviral | 13 (100) | 168 (96.5) | |
| Antiviral therapy post-OLT | 13/13 (100) | 172/174 (98.8) | |
| LAM | 12 | 129 | |
| ADV | 0 | 16 | |
| TDF | 0 | 3 | |
| ETV | 0 | 5 | |
| LAM+ADV | 1 | 14 | |
| LAM+TDF | 0 | 3 | |
| ADV+TDF | 0 | 2 | |
| Time of OLT (after 09.2002)1* | 6 (46.2) | 130 (74.7) | 0.077 |
| Duration of Steroid use (month) | 4.42 ± 2.7 | 4.7 ± 5.0 | 0.809 |
| Treatment for Rejection | 1 (7.6) | 26 (14.6) | 0.461 |
Results expressed as number (%) or mean ± SD unless specified otherwise
LAM: Lamivudine, ADV: Adefovir, TDF: Tenofovir, ETV: entecavir, HCC: Hepatocellular carcinoma
1
Date when adefovir was approved